uniQure (NASDAQ:QURE) Rating Reiterated by HC Wainwright

uniQure (NASDAQ:QURE)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Tuesday, Benzinga reports. They presently have a $25.00 price objective on the biotechnology company’s stock. HC Wainwright’s target price suggests a potential upside of 255.62% from the stock’s previous close.

Other research analysts have also recently issued research reports about the company. StockNews.com upgraded uniQure to a “sell” rating in a research report on Monday, August 5th. Mizuho decreased their price objective on uniQure from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 8th. The Goldman Sachs Group increased their price objective on uniQure from $6.00 to $10.00 and gave the company a “neutral” rating in a research note on Friday, August 2nd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $24.00 price objective on shares of uniQure in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, uniQure has a consensus rating of “Hold” and a consensus price target of $18.60.

uniQure Trading Up 3.7 %

Shares of QURE stock opened at $7.03 on Tuesday. uniQure has a fifty-two week low of $3.73 and a fifty-two week high of $11.35. The stock has a market cap of $341.30 million, a P/E ratio of -1.13 and a beta of 0.97. The business has a fifty day simple moving average of $6.52 and a 200-day simple moving average of $5.65. The company has a quick ratio of 7.36, a current ratio of 7.36 and a debt-to-equity ratio of 1.06.

Institutional Trading of uniQure

A number of hedge funds have recently added to or reduced their stakes in the business. Doheny Asset Management CA acquired a new stake in uniQure in the 2nd quarter worth about $1,220,000. Algert Global LLC purchased a new position in shares of uniQure in the 2nd quarter worth about $176,000. Cubist Systematic Strategies LLC raised its holdings in shares of uniQure by 130.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 25,494 shares of the biotechnology company’s stock worth $114,000 after purchasing an additional 14,454 shares during the period. Marshall Wace LLP purchased a new position in shares of uniQure in the 2nd quarter worth about $175,000. Finally, Vanguard Personalized Indexing Management LLC raised its holdings in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the period. 78.83% of the stock is owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.